Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion type Assertion NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_head.
- NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion description "[We describe two non-small-cell lung cancer (NSCLC) patients in which treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) gefitinib produced a prolonged control of bone disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_provenance.
- NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion evidence source_evidence_literature NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_provenance.
- NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion SIO_000772 18079016 NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_provenance.
- NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion wasDerivedFrom befree-20150227 NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_provenance.
- NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_assertion wasGeneratedBy ECO_0000203 NP368342.RAM1yB_FEq8UJI9X39VzTRQd6r0xlH8RzQ0jMEYhCO6FQ130_provenance.